Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Capital on the Frontier Measure Better Investing in Racial Equity Beyond Trade-offs Impact en las Americas New Revivalists
Local and Inclusive Climate Finance Catalytic Capital Frontier Finance Best Practices Geographies
Slack Agent of Impact Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Locavesting Entrepreneurship Gender Smart Return on Inclusion Good Jobs Creative economy Opportunity Zones Investing in place Housing New Schooled Well Being People on the Move Faith and investing Inclusive Fintech
Clean Energy Farmer Finance Soil Wealth Conservation Finance Financing Fish
Innovative Finance
Personal Finance Impact Management
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States
Subscribe Log In

CARB-X puts up $24 million to develop new antibiotics

CARB-X, a biopharma accelerator, is backing 11 companies with the funds, including three that are developing new strains of antibiotics.

The increase in antibiotic-resistant bacteria — largely due to over-prescription of antibiotics and their excessive use in animal agriculture — is a worrisome development for global health.

CARB-X launched last year as a partnership between the U.S. Department of Health and Human Services (HHS) and Wellcome Trust, a U.K.-based biomedical-research charity, to spur development of antibiotics and superbug therapeutics.

“Our target is that at a minimum, two products make it to human testing in five years,” Joe Larson, acting deputy director of the HHS agency overseeing CARB-X, told the Washington Post.

The alliance has earmarked $350 million over the next five years towards that goal. The 11 companies that received funds in the round will be able to tap an additional $24 million if they meet certain targets.

This post originally appeared in ImpactAlpha’s daily newsletter. Get The Brief.

Photo credit: NIAID

You might also like...